Latest Issue

Clinical & Experimental
Immunology

• Impact Factor: 2.853
• Submission
  to First Decision: 27 days
• Submission
  to Final Decision: 52 days
• Acceptance to Online Early: 31 days

Edited by Mark Peakman
Associate Editors: Marina Botto, Danny Douek, Matthias von Herrath

Clinical & Experimental Immunology is a top ranking, international journal publishing biologically significant studies that have clinical relevance. Providing an international forum for the publication of original research on all aspects of clinical immunology and translational immunology, Clinical & Experimental Immunology is amongst the foremost journals in this field, attracting high-quality papers from all parts of the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through basic scientific studies to the treatment, prevention or diagnosis of human disease. Clinical & Experimental Immunology presents clinical immunological studies covering: immunopathogenesis of communicable and parasitic diseases; rheumatic, renal and endocrine disorders; immunological disorders in other organ systems and malignancy and transplantation

News

2008 Impact Factor: CEI Leaps and Bounds!

With the publication of the latest ISI Impact Factors, Wiley-Blackwell is delighted that CEI has enjoyed a much-earned increase, rising to 2.853! Congratulations to Editor in Chief, Mark Peakman and his team of dedicated Associate Editors, as well as the many authors who have contributed towards this success.

Disclosure

We are encouraging authors to declare potential conflicts of interest, in order to allow the journal readership to make a balanced appraisal of the author(s) interests. Details are available here.

NIH Public Access Mandate

For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit www.wiley.com/go/nihmandate.